Skip to main content
SpringerLink
Log in

Nonlinear Binding of Valproic Acid (VPA) and E-Δ2-Valproic Acid to Rat Plasma Proteins

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

The binding characteristics of valproic acid (VPA) and its pharmacologically active monounsaturated metabolite, E-Δ2-VPA, to rat plasma proteins were compared. The plasma free fraction was determined by a rapid equilibrium procedure, which minimizes the interfering effects of nonesterified fatty acids liberated by in vitro lipolysis. Nonlinear binding behavior was observed with both compounds over their respective pharmacologic concentration range. Multiple binding-site models were invoked to explain the binding isotherm. The 2-unsaturated compound has a much higher affinity for the rat plasma proteins (mainly albumin) than its saturated precursor. The equilibrium association constants for the high- and intermediate-affinity sites were more than an order of magnitude higher with E-Δ2-VPA than with VPA (104–106 versus 103 M −1). This difference in binding affinity was also reflected by a lower plasma free fraction for E-Δ2-VPA compared with VPA (<<10 versus >20% at total concentrations of less than 100 µg/ml). A more pronounced dose- and concentration-dependent variation in the distribution and clearance kinetics is predicted for the 2-unsaturated analogue compared to VPA. Also, the structural dependency in plasma protein binding observed with these branched-chain fatty acids may provide insights into the mechanism of interaction between fatty acyl molecules and albumin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. F. E. Dreifuss, N. Santilli, D. H. Langer, K. P. Sweeney, K. A. Moline, and K. B. Menander. Neurology 37:379–385 (1987).

    Google Scholar 

  2. T. Bjerkedal. International clearing house for birth defects monitoring systems. Lancet 2:1096 (1982).

    Google Scholar 

  3. W. Löscher and H. Nau. Neuropharmacology 24:427–435 (1985).

    Google Scholar 

  4. P. E. Keane, J. Simiand, and M. Morre. Meth. Find. Exp. Clin. Pharmacol. 7:83–86 (1985).

    Google Scholar 

  5. F. S. Abbott and A. Acheampong. Neuropharmacology 27:287–294 (1988).

    Google Scholar 

  6. H. Nau. Teratology 33:21–27 (1986).

    Google Scholar 

  7. C. Lewandowski, S. Klug, H. Nau, and D. Neubert. Arch. Toxicol. 58:239–242 (1986).

    Google Scholar 

  8. J. W. Kesterson, G. R. Granneman, and J. M. Machinist. Hepatology 4:1143–1152 (1984).

    Google Scholar 

  9. H. Schafer and R. Luhrs. In R. H. Levy, W. H. Pitlick, M. Eichelbaum, and J. Meijer (eds.), Metabolism of Antiepileptic Drugs, Raven Press, New York, 1984, pp. 73–81.

    Google Scholar 

  10. U. Klotz and K. H. Antonin. Clin. Pharmacol. Ther. 21:736–743 (1977).

    Google Scholar 

  11. U. Klotz, T. Rapp, and W. A. Muller. Eur. J. Clin. Pharmacol. 13:55–60 (1978).

    Google Scholar 

  12. T. A. Bowdle, I. H. Patel, R. H. Levy, and A. J. Wilensky. Clin. Pharmacol. Ther. 28:486–492 (1980).

    Google Scholar 

  13. H.-Y. Yu, Y.-Z. Shen, Y. Sugiyama, and M. Hanano. Epilepsia 28:680–687 (1987).

    Google Scholar 

  14. H. Nau, H. Helge, and W. Luck. J. Pediat. 104:627–634 (1984).

    Google Scholar 

  15. W. Löscher, H. Nau, and H. Siemes. Epilepsia 29:311–316 (1988).

    Google Scholar 

  16. W. Löscher and H. Nau. Arch. Int. Pharmacodyn. 270:192–202 (1984).

    Google Scholar 

  17. A. Monks and A. Richens. Br. J. Clin. Pharmacol. 8:187–189 (1979).

    Google Scholar 

  18. I. H. Patel and R. H. Levy. Epilepsia 20:85–90 (1979).

    Google Scholar 

  19. C. L. Zimmerman, I. H. Patel, R. H. Levy, D. Edwards, S. D. Nelson, and M. Hutchinson. Epilepsia 22:11–17 (1981).

    Google Scholar 

  20. T. A. Bowdle, I. H. Patel, R. H. Levy, and A. J. Wilensky. Eur. J. Clin. Pharmacol. 23:343–347 (1982).

    Google Scholar 

  21. F. Albani, R. Riva, G. Procaccianti, A. Baruzzi, and E. Perucca. Epilepsia 24:65–73 (1983).

    Google Scholar 

  22. R. Riva, F. Albani, M. Contin, A. Baruzzi, M. Altomare, G. P. Merlini, and E. Perucca. Ther. Drug Mon. 6:25–30 (1984).

    Google Scholar 

  23. K. M. Giacomini, S. Swezey, K. C. Giacomini, and T. F. Blaschke. Life Sci. 27:771–780 (1980).

    Google Scholar 

  24. M. J. Ridd, K. F. Brown, R. G. Moore, and R. L. Nation. Int. J. Pharm. 11:11–20 (1982).

    Google Scholar 

  25. R. Riva, F. Albani, A. Baruzzi, I. Galvani, and E. Perucca. Ther. Drug Mon. 4:341–352 (1982).

    Google Scholar 

  26. P. J. McNamara and J. B. Bogardus. J. Pharm. Sci. 71:1066–1068 (1982).

    Google Scholar 

  27. H. E. Rosenthal. Anal. Biochem. 20:525–532 (1967).

    Google Scholar 

  28. M. Ralston. In W. J. Dixon et al. (eds.), BMDP Statistical Software, University of California Press, Berkeley, 1985, pp. 305–314.

    Google Scholar 

  29. R. L. Priore and H. E. Rosenthal. Anal. Biochem. 70:231–240 (1976).

    Google Scholar 

  30. K. Yamaoka, T. Nakagawa, and T. Uno. J. Pharmacokinet. Biopharm. 6:165–175 (1978).

    Google Scholar 

  31. R. L. O. Semmes and D. D. Shen. J. Chromatogr. 432:185–197 (1988).

    Google Scholar 

  32. K. M. Giacomini, A. Abang, and T. F. Blaschke. Br. J. Clin. Pharmacol. 14:752–753 (1982).

    Google Scholar 

  33. S. R. Bergman, E. Carlson, E. Dannen, and B. E. Sobel. Clin. Chem. Acta 104:53–63 (1980).

    Google Scholar 

  34. B. Rosner. Fundamentals of Biostatistics, Duxbury Press, Boston, 1982, pp. 232–237, 418–424.

    Google Scholar 

  35. B. J. Jordan, J. S. Shillingford, and K. P. Steed. In N. L. Legg (ed.), Clinical and Pharmacological Aspects of Sodium Valproate (Epilim) in the Treatment of Epilepsy, MCS Consultants, Tunbridge Wells, Kent, 1976, pp. 112–118.

    Google Scholar 

  36. J. Barre, J. M. Chamouard, G. Houin, and J. P. Tillement. Clin. Chem. 31:60–64 (1985).

    Google Scholar 

  37. H. Vorum, S. Andersen, and R. Broderson. Epilepsia 30:370–373 (1989).

    Google Scholar 

  38. S. W. M. Koh and G. E. Means. Arch. Biochem. Biophys. 192:73–79 (1979).

    Google Scholar 

  39. D. S. Goodman. J. Am. Chem. Soc. 80:3892–3898 (1958).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, School of Pharmacy, University of Washington, BG-20, Seattle, Washington, 98195

    Robin L. O. Semmes & Danny D. Shen

Authors
  1. Robin L. O. Semmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danny D. Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Semmes, R.L.O., Shen, D.D. Nonlinear Binding of Valproic Acid (VPA) and E-Δ2-Valproic Acid to Rat Plasma Proteins. Pharm Res 7, 461–467 (1990). https://doi.org/10.1023/A:1015804413818

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015804413818

Search

Navigation